2026-05-05T15:21:12.070Z / 美国有线电视新闻网（CNN）
作者：蒂尔尼·斯尼德
9分钟前发布
发布于美国东部时间2026年5月5日上午11:21
堕胎权利 唐纳德·特朗普 最高法院 联邦机构
查看所有主题
反堕胎活动人士参加1月23日在华盛顿特区举行的年度生命游行集会。
凯文·迪特施/盖蒂图片社
堕胎问题再次提交最高法院，这正对总统唐纳德·特朗普回避该议题的策略构成考验。反堕胎活动人士日益感到沮丧，认为其政府在限制米非司酮——这种获批用于终止妊娠的药物——的获取方面并未采取更多行动。
特朗普政府保留了拜登时代让堕胎药物更易获取的监管框架，这在很大程度上让该议题脱离了两党政治的焦点。但上周五，保守派上诉法院的一项裁决打乱了这一思路，该裁决要求获取堕胎药物必须进行线下问诊，将在全国范围内限制药物堕胎的渠道。
美国第五巡回上诉法院的这项裁决，对于起诉特朗普政府、要求其收紧米非司酮监管规则的反堕胎州官员和活动人士来说是重大胜利。他们认为，允许通过线上问诊获取该药物，正在削弱各州限制堕胎的法律。
如果由6名保守派大法官和3名自由派大法官组成的最高法院不像米非司酮制造商目前所请求的那样暂停该裁决，那么在中期选举临近之际，全国范围内的堕胎药物获取渠道将受到限制。
“令人震惊的是，特朗普政府的不作为阻碍了亲生命法案生效，迫使多名共和党总检察长将诉讼提交至联邦法院，”支持反堕胎候选人的苏珊·B·安东尼亲生命美国组织的通讯主任凯尔西·普里查德说道。
该组织周一再次呼吁解雇美国食品药品监督管理局局长马蒂·马卡里，白宫此前已多次拒绝这一要求。
“我们实在难以理解，特朗普政府为何如此疏忽，任由这项政策保留至今，”普里查德补充道。
在下级法院审理过程中，特朗普政府试图采取折中策略：以程序合规性为由反对路易斯安那州总检察长莉兹·莫里尔提起的诉讼，但并未直接为该药物的安全性辩护。
“很明显，他们不想在中期选举前作出裁决，剥夺全美女性获取米非司酮的渠道，”拜登政府时期担任美国卫生与公众服务部总法律顾问、曾在法庭上为FDA的相关规则辩护的萨姆·巴根斯托斯说道。
“不过，”巴根斯托斯补充道，“他们正尽其所能保留自身能力，一旦摆脱选举压力，就会立即剥夺全美女性获取米非司酮的渠道。”
即便特朗普政府保持沉默，也可能给其带来政治问题。民主党已经借此大做文章，民主党全国委员会周一在一份声明中指责特朗普“禁止已安全使用数十年的药物，使获取救命的生殖健康服务难上加难”。
当被CNN问及特朗普是否支持第五巡回上诉法院的裁决时，白宫并未直接回应。相反，一位发言人发表声明称，美国食品药品监督管理局正在对米非司酮进行“基于科学的金标准审查”，以“解决人们对其使用安全性的广泛担忧”。
美国司法部同样援引这项审查——预计将持续至少数月——主张暂停对相关监管规则的诉讼。
顶住压力支持监管负责人
反堕胎活动人士越来越怀疑，这项审查只是政府拖延该议题的手段——FDA此前否认了这一说法。本周末《华尔街日报》的一篇报道称马卡里对米非司酮的监管规定漠不关心，这加剧了活动人士的担忧。
路易斯安那州提交的法庭文件显示，一名司法部律师在诉讼程序中仅承诺，部分审查内容“可能”在2027年前完成。
“随着此案推进，当前仅围绕程序问题展开的策略将越来越站不住脚，”加州大学戴维斯分校法学教授、多部反堕胎运动相关著作作者玛丽·齐格勒说道，“第五巡回法院打破了这一策略。”
特朗普曾吹嘘自己任命了2022年推翻“罗伊诉韦德案”的五名大法官中的三位，他支持大法官塞缪尔·阿利托在多数意见中提出的框架，即将堕胎问题交还给各州自行决定。
相关报道：2023年4月20日，伊利诺伊州卡本代尔阿拉莫妇女诊所的患者准备服用米非司酮。伊芙琳·霍克斯坦/路透社 最高法院暂时恢复通过邮寄获取堕胎药物米非司酮的权利 3分钟阅读
但药物堕胎——即通过两片药物组合终止妊娠的方式——表明这一做法说起来容易做起来难。自2022年最高法院裁决以来，全美堕胎总数有所上升，药物堕胎目前占所有堕胎案例的三分之二左右，如今已成为反堕胎运动的首要打击目标。
多项审查结果显示米非司酮安全性良好。2024年，最高法院驳回了反堕胎医生对该药物获取渠道的挑战，认定这些医生并未证明现行监管规则对其造成了值得法院干预的损害。
自连任以来，特朗普已经推行了反堕胎活动人士寻求的部分政策。但他任命的联邦卫生机构负责人并未表现出出台限制药物堕胎监管规则的意愿。苏珊·B·安东尼亲生命组织发言人普里查德认为，特朗普在监管规则上无所作为，将削弱共和党基础选民在中期选举中的投票热情，她援引了CNN2024年的出口民调数据。
“如果2024年有1%到2%的亲生命选民待在家里不投票，特朗普就不会当选总统，”她说道。
白宫显然在进行相反的赌博，选择支持马卡里。
白宫发言人库什·德赛告诉CNN：“马卡里继续为美国民众服务，从现代化药品审批流程到打击我们食品供应中的人工成分。”
最高法院案件的下一步进展
最高法院已对第五巡回法院的裁决下达短暂的“行政”暂停令，允许远程医疗堕胎服务继续进行，暂停期限至5月11日。法院已要求路易斯安那州于周四提交辩护状。美国司法部发言人未回应CNN关于其是否会在此期限前提交辩护状的问询。
米非司酮制造商提出的后续方案之一是，最高法院现在可以就案件实质问题进行审理，并在未来几周内举行听证会。
最高法院暂时恢复通过邮寄获取堕胎药物米非司酮的权利
1:55
齐格勒表示，就目前而言，政府可以继续主张路易斯安那州的诉讼应因程序问题被驳回，并坚持其不明确表态米非司酮安全性、允许线上购买该药物的策略。
“我认为复杂的地方在于，大法官们是否愿意进一步介入此案，”她说道。
不过，在将2023年“罗伊诉韦德案”的推翻结果描述为将政策辩论交由州议员决定后，最高法院可能并不急于再次卷入具有全国影响力的堕胎争议。
密歇根大学法学院教授巴根斯托斯表示，特朗普政府最终“要么必须明确表态，要么闭嘴——他们需要明确立场，说明米非司酮是否被适当地批准用于终止妊娠，以及是否本应取消线下配药要求”。“他们需要很快这么做吗？这完全取决于最高法院的裁决。”
堕胎权利 唐纳德·特朗普 最高法院 联邦机构
查看所有主题
Supreme Court abortion case could force Trump to take a public stance on mifepristone
2026-05-05T15:21:12.070Z / CNN
By Tierney Sneed
9 min ago
PUBLISHED May 5, 2026, 11:21 AM ET
Abortion rights Donald Trump Supreme Court Federal agencies
See all topics
Anti-abortion activists participate in the annual March for Life rally on January 23 in Washington, DC.
Kevin Dietsch/Getty Images
The return of abortion to the Supreme Court is testing President Donald Trump’s strategy of avoiding the issue as the anti-abortion advocates grow increasingly frustrated that his administration hasn’t done more to crack down on access to mifepristone, the drug approved to terminate pregnancies.
By leaving intact a Biden-era regulatory regime that made abortion pills easier to obtain, Trump’s administration has mostly kept the issue off the political front burner for both parties. But a conservative appeals court threw wrench in that approach Friday, with a ruling that would add limits to access nationwide by requiring in-person doctor’s visits to obtain the pills.
The ruling from the US 5th Circuit Cout of Appeals is a major win for anti-abortion state officials and advocates who sued the Trump administration to force it to tighten the rules for mifepristone. They argue that allowing the medication to be obtained by online appointments was undermining state laws restricting abortion.
If the 6-3 conservative Supreme Court doesn’t freeze the ruling, as mifepristone manufacturers are now asking, it will limit access to abortion nationwide as the midterms approach.
“What is shocking is that the Trump administration’s inaction has stopped pro-life laws from taking effect, and that they forced several Republican attorneys general to take their battle to the federal courts,” said Kelsey Pritchard, the communications director for Susan B. Anthony Pro-Life America, which supports anti-abortion candidates.
The group on Monday reiterated its calls that US Food and Drug Administration head Marty Makary be fired, which the White House has repeatedly rebuffed.
“It’s just really hard for us to understand how the Trump administration has been so negligent as to leave this policy in place,” Pritchard added.
In lower courts, the Trump administration has tried to thread the needle by pushing back on the lawsuit, brought by Louisiana Attorney General Liz Murrill, for procedural reasons while not defending the safety of the drug outright.
“It’s clear that they do not want to have a ruling taking access to mifepristone away from women across the country before the midterms,” said Sam Bagenstos, who was general counsel for US Department of Health and Human Services during the Biden administration and who defended the FDA rules in court then.
“However,” Bagenstos added, “they are doing everything they can to preserve their ability to take access to mifepristone away from women across the country as soon as they’re out of the woods.”
Even the administration’s silence could be a political problem for Trump as Democrats are already seizing on the case, with the Democratic National Committee accusing Trump in a statement Monday of making “it even harder to get lifesaving reproductive healthcare by banning medication that has been safely used for decades.”
Asked by CNN whether Trump supports the 5th Circuit ruling, the White House did not answer the question directly. Instead, a spokesperson issued a statement pointing to the “Gold Standard Science-based review of mifepristone” that the US Food and Drug Administration is conducting “to address widespread safety concerns about its use.”
The Justice Department has similarly pointed to that review – which is expected to last at least several months – to argue the lawsuit challenging the regulations should be paused.
Standing by regulatory chief under fire
Anti-abortion advocates have grown to suspect the review is just a way for the administration to slow-walk the issue – a claim that the FDA has previously denied. Their concerns were exacerbated by a Wall Street Journal report this weekend indicating Makary had expressed indifference to regulations for mifepristone.
Court briefs from Louisiana noted how a Justice Department lawyer could promise in the proceedings only that parts of the review “’might’ be done by 2027.
“As this case moves along, the current game plan about making this only about procedural issues is going to become more and more untenable,” said Mary Ziegler, a law professor at University of California, Davis, and author of several books about the anti-abortion movement. “The 5th Circuit blew up that strategy.”
Trump, touting his appointment of three of the five justices who overturned Roe v. Wade in 2022, has embraced the way that ruling was framed in the majority opinion by Justice Samuel Alito as returning the issue to the states to decide for themselves.
Related article: A patient prepares to take Mifepristone at Alamo Women’s Clinic in Carbondale, Illinois, on April 20, 2023. Evelyn Hockstein/Reuters Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail 3 min read
But medication abortion – the two-pill regimen that terminates a pregnancy – has shown such an approach is easier said than done. The method now makes up some two-thirds of all US abortions – as the number of abortions overall has increased since the 2022 Supreme Court ruling – and now it’s the top target of the anti-abortion movement.
Reviews of mifepristone have found it to be safe. The Supreme Court in 2024 rejected a challenge to the pill’s access brought by anti-abortion doctors, concluding that the physicians hadn’t shown they were being harmed by the current regulations in a way that would warrant a court’s intervention.
Since his reelection, Trump has enacted some policies sought by abortion opponents. But his appointees to lead federal health agencies have not shown interest in implementing regulatory changes that would limit access to medication abortion. Pritchard, the SBA List spokesperson, argued that Trump’s refusal to act on the regulations will dampen turnout by Republicans’ base in the midterms as she pointed to CNN exit polling from 2024.
“If 1-2% of pro-lifers had stayed home in 2024, Trump wouldn’t be president,” she said.
The White House is apparently making the opposite gamble and standing by Makary.
Makary “continues to deliver for the American people, from modernizing the drug approvals process to cracking down on artificial ingredients in our food supply,” White House spokesperson Kush Desai told CNN.
What comes next in the Supreme Court case
The Supreme Court has put the 5th Circuit ruling on a brief “administrative” hold, allowing telehealth abortions to continue, until May 11. Louisiana has been asked to file briefs on Thursday. A DOJ spokesperson did not respond to CNN’s inquiry as to whether it will file briefs by then as well.
Among the options for next steps put forward by the mifepristone manufacturers is the possibility that the Supreme Court could take up the case on the merits now, hearing arguments in the coming weeks.
Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail
1:55
For now, according to Ziegler, the administration could hold on to the arguments that Louisiana’s lawsuit should be thrown out for procedural reasons and maintain its approach of not spelling out its views on the safety of mifepristone and allowing it to be procured online.
“What I think will get complicated is if the justices have the appetite for anything more,” she said.
However, the Supreme Court itself might not be eager to jump into another abortion dispute that has nationwide implications, after framing its 2023 Roe reversal as putting the policy debate in the hands of state legislators.
The Trump administration is eventually “going to have to put up or shut up about their position regarding whether mifepristone was appropriately approved for termination of pregnancy and whether the in-person dispensing requirement should have been eliminated,” Bagenstos, now a University of Michigan Law School professor, said. “Are they going to have to do that soon? You know, it all depends on what the Supreme Court does.”
Abortion rights Donald Trump Supreme Court Federal agencies
See all topics
发表回复